Agenus Inc. (AGEN) News
Track canonical SquawkNews coverage tagged to AGEN, Agenus Inc.. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 8 indexed stories across 8 publication days and is ordered by the same first-publication timeline used by LiveCast.
L
Agenus to Present Three-Year Overall Survival Data for BOT+BAL in Recurrent Ovarian Cancer at IGCS 2026
Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that a poster evaluating botensilimab (BOT), an Fc-enhanced multifunctional anti-CTLA-4 antibody, in combination with balstilimab (BAL),
EQUITY | Sep 10, 2026, 11:30 AM UTC
L
Agenus announces peer-reviewed publication on BOT+BAL in MSS metastatic CRC
Agenus says a peer-reviewed publication links BOT+BAL’s durable survival in MSS metastatic colorectal cancer to its immune-priming mechanism.
EQUITY | Aug 28, 2026, 02:07 PM UTC
L
Agenus updates NEST Phase 2 publication in resectable colon cancer
Agenus says it has published updated Phase 2 NEST results for neoadjuvant BOT+BAL in resectable colon cancer, citing deep pathologic responses and no observed recurrences.
EQUITY | Aug 26, 2026, 02:05 PM UTC
L
AGEN Agenus files to sell 2.13M shares of common stock for holders
AGEN Agenus files to sell 2.13M shares of common stock for holders
EQUITY | Jul 20, 2026, 10:54 AM UTC
H
Stock Market Today: Dow Jones Futures Fall, Nasdaq 100 Gains as Trump Calls US the 'Guardian' of Hormuz Strait—Tower Semiconductor, Twin Vee
U.S. stock futures were mixed on Tuesday, as the Nasdaq 100 index advanced, while the Dow Jones and S&P 500 indices fell, following Monday’s lower close. As the U.S. and Iran attacks continued for the third straight nigh
CENTRAL_BANK | Jul 14, 2026, 09:28 AM UTC
L
Agenus announces strategic prioritization of neoadjuvant BOT+BAL
Agenus announces strategic prioritization of neoadjuvant BOT+BAL
EQUITY | Jul 13, 2026, 04:19 PM UTC
L
Agenus Reports Landmark BOT+BAL Data Showing 33% Three-Year Overall Survival in Refractory MSS Metastatic Colorectal Cancer Without Active L
Agenus Reports Landmark BOT+BAL Data Showing 33% Three-Year Overall Survival in Refractory MSS Metastatic Colorectal Cancer Without Active Liver Metastases at ESMO GI 2026
EQUITY | Jul 06, 2026, 11:30 AM UTC
M
AGEN Presents Survival Data
Agenus announces three-year survival data from Phase 1b BOT+BAL study in MSS metastatic colorectal cancer to be presented at ESMO GI 2026
EQUITY | Jun 25, 2026, 11:00 AM UTC